Investigational drug · Phase 3
GB06
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children, Growth Hormone Deficiency, Pediatric.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "GB06"
First trial start
2026
Jun 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GB06", any sponsor or status.
Conditions studied
As listed on its trial records.
- Growth Hormone Deficiency (GHD)
- Growth Hormone Deficiency in Children
- Growth Hormone Deficiency, Pediatric
Approved drugs for the same conditions: Growth hormone deficiency · Rare and genetic disease · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "GB06" as an intervention, largest first.
- GB06 Phase III Trial for Pediatric Growth Hormone DeficiencyPivotal-lookingRecruiting
Kexing Biopharm Co., Ltd.Industry
NCT07553351 · 192 participants (planned) · Start Jun 6, 2026 · Primary completion Jul 25, 2028
Drug: GB06; Norditropin®FlexProTM · For: Growth Hormone Deficiency (GHD); Growth Hormone Deficiency in Children; Growth Hormone Deficiency, Pediatric
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- Loktanella spp. Gb03 as an algicidal bacterium, isolated from the culture of Dinoflagellate Gambierdiscus belizeanus.
Bloh AH, Usup G, Ahmad A · Vet World 2016
Also in development for Growth Hormone Deficiency (GHD)
- LUM-201Phase 36 trials
Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.